Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

26.53
+0.72002.79%
Post-market: 15.05-11.4800-43.27%19:59 EDT
Volume:7.17M
Turnover:139.68M
Market Cap:2.61B
PE:-4.55
High:26.80
Open:25.96
Low:25.57
Close:25.81
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:80.72M
Volume Ratio:4.36
T/O Rate:8.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.96
PE(LYR):-4.55

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

Ultragenyx announces FDA clearance of UX016 investigational new drug application

TIPRANKS
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BUZZ-Ultragenyx rises after FDA clears human trial for rare muscle disease drug

Reuters
·
Mar 30

Ultragenyx wins FDA IND clearance for UX016 in GNE myopathy

Reuters
·
Mar 30

Ultragenyx Pharmaceutical Inc - Phase 1/2 Study of Ux016 Expected to Begin in H2 2026

THOMSON REUTERS
·
Mar 30

Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump?

Simply Wall St.
·
Mar 29

Ultragenyx announces annual stockholders meeting; FY2025 revenue grows 20%

Reuters
·
Mar 28

BROAD ARROW PRESENTS RARE OPPORTUNITY TO ACQUIRE FERRARI MONZA SP2 AT CONCORSO D’ELEGANZA VILLA D’ESTE AUCTION

GlobeNewswire
·
Mar 27

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Mar 25

Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results

Simply Wall St.
·
Mar 25

Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61

MT Newswires Live
·
Mar 24

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

TIPRANKS
·
Mar 24

Ultragenyx grants 10,839 restricted stock units under employment inducement plan

Reuters
·
Mar 21

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 21

Analysts Conflicted on These Healthcare Names: Immutep (IMMP) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Mar 15

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Benzinga_recent_news
·
Mar 13

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Reuters
·
Mar 12

Ultragenyx Phase 3 Enh3ance study showed statistically significant results

TIPRANKS
·
Mar 12

Ultragenyx reports Phase 3 Enh3ance trial shows DTX301 cuts plasma ammonia AUC by 18% at Week 36

Reuters
·
Mar 12